Skip Nav Destination

Issue Archive

Select Year

Issue

Volume 1, Issue 1

March 21 2024

In this Issue

CLINICAL TRIALS AND OBSERVATIONS
LYMPHOID NEOPLASIA
MYELOID NEOPLASIA
RESEARCH LETTER

CLINICAL TRIALS AND OBSERVATIONS

KIR3DL1-HLA-Bw status in CML is associated with achievement of TFR: the POKSTIC trial, a multicenter observational study
Clinical Trials & Observations

Hiroshi Ureshino,Yasunori Ueda,Shin Fujisawa,Kensuke Usuki,Hideo Tanaka,Masaya Okada,Shugo Kowata,Kazunori Murai,Asao Hirose,Motohiro Shindo,Takashi Kumagai,Tomoharu Takeoka,Kazuharu Kamachi,Keisuke Kidoguchi,Takero Shindo,Satoshi Iyama,Junki Inamura,Takafumi Nakao,Tsutomu Kobayashi,Eri Kawata,Hiroshi Ohkawara,Takayuki Ikezoe,Atsushi Kawaguchi,Shinya Kimura

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

Patients with Castleman disease report mild COVID-19 symptoms and mount a humoral response to SARS-CoV-2 vaccination
Clinical Trials & Observations

Saishravan Shyamsundar,Sheila K. Pierson,Caoilfhionn M. Connolly,Mayan Teles,Dorry L. Segev,William A. Werbel,Frits van Rhee,Corey Casper,Joshua D. Brandstadter,Ariela Noy,David C. Fajgenbaum

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

LYMPHOID NEOPLASIA

Real-world comparison of daratumumab-based regimens in relapsed/refractory multiple myeloma using health record data

Benjamin A. Derman,Jacob Ambrose,Laura L. Fernandes,Christina M. Zettler,Eric Hansen,Andrew J. Belli,Ching-Kun Wang

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

MYELOID NEOPLASIA

Comparison of TP53 mutations in myelodysplasia and acute leukemia suggests divergent roles in initiation and progression

Ashwini Jambhekar,Emily E. Ackerman,Berk A. Alpay,Galit Lahav,Scott B. Lovitch

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

RESEARCH LETTER

Multiple myeloma–associated DIS3 gene is essential for hematopoiesis, but loss of DIS3 is insufficient for myelomagenesis

Hiroto Ohguchi,Yasuyo Ohguchi,Sho Kubota,Kan Etoh,Ai Hamashima,Shingo Usuki,Takako Yokomizo-Nakano,Jie Bai,Takeshi Masuda,Yawara Kawano,Takeshi Harada,Mitsuyoshi Nakao,Takashi Minami,Teru Hideshima,Kimi Araki,Goro Sashida

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

Cover Image

Cover Image

Illustration of lymphocytes attacking a cancer cell. Source: Christoph Burgstedt/Science Photo Library.

All Issues

Advertisement intended for health care professionals

Table of Contents

CLINICAL TRIALS AND OBSERVATIONS

KIR3DL1-HLA-Bw status in CML is associated with achievement of TFR: the POKSTIC trial, a multicenter observational study
Clinical Trials & Observations

Patients with Castleman disease report mild COVID-19 symptoms and mount a humoral response to SARS-CoV-2 vaccination
Clinical Trials & Observations

LYMPHOID NEOPLASIA

Real-world comparison of daratumumab-based regimens in relapsed/refractory multiple myeloma using health record data

MYELOID NEOPLASIA

Comparison of TP53 mutations in myelodysplasia and acute leukemia suggests divergent roles in initiation and progression

RESEARCH LETTER

Multiple myeloma–associated DIS3 gene is essential for hematopoiesis, but loss of DIS3 is insufficient for myelomagenesis

ASH Publications

American Society of Hematology

Issue Archive

Table of Contents

CLINICAL TRIALS AND OBSERVATIONS

KIR3DL1-HLA-Bw status in CML is associated with achievement of TFR: the POKSTIC trial, a multicenter observational study Clinical Trials & Observations

Patients with Castleman disease report mild COVID-19 symptoms and mount a humoral response to SARS-CoV-2 vaccination Clinical Trials & Observations

LYMPHOID NEOPLASIA

Real-world comparison of daratumumab-based regimens in relapsed/refractory multiple myeloma using health record data

MYELOID NEOPLASIA

Comparison of TP53 mutations in myelodysplasia and acute leukemia suggests divergent roles in initiation and progression

RESEARCH LETTER

Multiple myeloma–associated DIS3 gene is essential for hematopoiesis, but loss of DIS3 is insufficient for myelomagenesis

Cover Image

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

KIR3DL1-HLA-Bw status in CML is associated with achievement of TFR: the POKSTIC trial, a multicenter observational study
Clinical Trials & Observations

Patients with Castleman disease report mild COVID-19 symptoms and mount a humoral response to SARS-CoV-2 vaccination
Clinical Trials & Observations